Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2.

Manisha PandeyVictoria OzberkSharareh EskandariAhmed O ShalashMichael A JoyceHolly A SaffranChristopher J DayAilin LepletierBelinda L SpillingsJamie-Lee MillsAinslie CalcuttFan FanJames T WilliamsDanielle I StanisicLaetitia HattinghJohn GerrardMariusz SkwarczynskiJohnson MakMichael P JenningsIstvan TothD Lorne TyrrellMichael F Good

Published in: Clinical & translational immunology (2021)

COVID-19 convalescent patients have SARS-CoV-2-specific antibodies and MBCs, the specificities of which can be defined with short peptides. Epitope-specific antibodies synergistically block RBD-ACE2 interaction.

Keyphrases

sars cov
respiratory syndrome coronavirus
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
coronavirus disease
angiotensin ii
angiotensin converting enzyme
transcription factor